<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="29986">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01742117</url>
  </required_header>
  <id_info>
    <org_study_id>11-006837</org_study_id>
    <nct_id>NCT01742117</nct_id>
  </id_info>
  <brief_title>Tailored Antiplatelet Therapy Following PCI</brief_title>
  <acronym>TAILOR-PCI</acronym>
  <official_title>Tailored Antiplatelet Initiation to Lesson Outcomes Due to Decreased Clopidogrel Response After Percutaneous Coronary Intervention (TAILOR-PCI)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Mayo Clinic</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Applied Health Research Centre (AHRC)</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Mayo Clinic</source>
  <oversight_info>
    <authority>United States: Institutional Review Board</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Clopidogrel is an anti-platelet medication approved by the U.S. Federal Drug Administration
      (FDA) for use in patients who undergo Percutaneous Coronary Intervention (PCI) with coronary
      stent implantation. Anti-platelet medications work to prevent blood clots from forming. Some
      studies have suggested that patients who have a certain genetic liver enzyme abnormality
      (known as cytochrome P450 2C19 [CYP2C19] *2 or *3 allele) may have a reduced ability to
      activate clopidogrel, and therefore may have a lowered response to clopidogrel.  It is
      thought that perhaps people who have a coronary stent procedure may have this genetic liver
      enzyme abnormality. There is a research genetic test available to determine whether or not
      someone has this genetic liver enzyme abnormality.  Ticagrelor, is a newer anti-platelet
      drug that is not dependent on the CYP2C19 liver enzyme for its activation and hence in poor
      clopidogrel metabolizers, alternative drugs like Ticagrelor have been recommended for use as
      an anti-platelet agent after PCI. The purpose of this study is to determine if genetic
      testing can identify the best anti-platelet therapy, for patients who undergo a coronary
      stent placement and do not activate clopidogrel very well.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      TAILOR-PCI is a multi-site, open label, prospective, randomized trial testing the hypothesis
      that after percutaneous coronary intervention (PCI), using a genotyping strategy ticagrelor
      90 mg twice per day is superior to clopidogrel 75 mg per day in reducing a composite
      endpoint of major adverse cardiovascular events (MACE), i.e., non-fatal myocardial
      infarction, non-fatal stroke, severe recurrent ischemia, cardiovascular (CV) death, and
      stent thrombosis (primary endpoints) in CYP2C19 reduced function allele patients. Patients
      who undergo PCI will be randomized to a conventional therapy arm (i.e., to receive
      clopidogrel 75 mg once daily without prospective genotyping guidance) versus a prospective
      CYP2C19 genotype-based anti-platelet therapy approach (ticagrelor 90 mg bid in CYP2C19 *2 or
      *3 reduced function allele patients, clopidogrel 75 mg once daily in non-*2 or -*3 CYP2C19
      patients).  Buccal swabs will be obtained for those subjects randomized to the prospective
      genotyping arm. All subjects will have a blood sample drawn for DNA analysis but genotyping
      using these DNA samples will be performed only after completion of the duration of
      anti-platelet therapy (i.e., after one year).  The primary endpoints will be assessed
      prospectively and will be compared between the conventional arm and the prospective
      genotyping arm among those identified as reduced function CYP2C19 allele carriers according
      to the 1-year genotype results.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>May 2013</start_date>
  <completion_date type="Anticipated">August 2016</completion_date>
  <primary_completion_date type="Anticipated">June 2016</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Occurrence of the a major adverse cardiovascular event (MACE)</measure>
    <time_frame>Randomization, one year after percutaneous coronary intervention (PCI)</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>MACE will include non-fatal myocardial infarction, non-fatal stroke, cardiovascular mortality, severe recurrent ischemia, and stent thrombosis</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of subjects with reduced function CYP2C19 allele(s) who have major or minor bleeding</measure>
    <time_frame>One year after PCI</time_frame>
    <safety_issue>Yes</safety_issue>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">5270</enrollment>
  <condition>Coronary Artery Disease</condition>
  <condition>Acute Coronary Syndrome</condition>
  <condition>Stenosis</condition>
  <arm_group>
    <arm_group_label>Clopidogrel then Retrospective Genotyping</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Standard clinical practice of clopidogrel 75 mg daily for one year following PCI.  DNA samples taken at baseline will be frozen, then at 12 months will be genotype tested to determine the *2 &amp; *3 reduced function or wild type allele status.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Prospective Genotyping - Clopidogrel</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients with the wild type CYP2C19 allele (based on prospective genotype testing) will be assigned to receive a clopidogrel 75mg tablet daily for one year following PCI.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Prospective Genotyping - Ticagrelor</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients with the CYP2C19 heterozygous and homozygous *2 and *3 reduced function allele (based on prospective genotype testing) will be assigned to receive a ticagrelor 90 mg tablet twice per day for one year following PCI.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Clopidogrel</intervention_name>
    <description>Subjects will receive Clopidogrel, one 75 mg tablet per day by mouth for one year.</description>
    <arm_group_label>Clopidogrel then Retrospective Genotyping</arm_group_label>
    <arm_group_label>Prospective Genotyping - Clopidogrel</arm_group_label>
    <other_name>Plavix</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ticagrelor</intervention_name>
    <description>Subjects will receive Ticagrelor, one 90 mg tablet twice per day by mouth.</description>
    <arm_group_label>Prospective Genotyping - Ticagrelor</arm_group_label>
    <other_name>Brilinta</other_name>
  </intervention>
  <intervention>
    <intervention_type>Genetic</intervention_type>
    <intervention_name>Retrospective Genotype testing</intervention_name>
    <description>Mayo Clinic will use ABI TaqMan assay of three variants in the CYP2C10 gene:  *2, *3 and *17</description>
    <arm_group_label>Clopidogrel then Retrospective Genotyping</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Genetic</intervention_type>
    <intervention_name>Prospective Genotype testing</intervention_name>
    <description>Rapid turnaround Spartan^TM Bioscience in vitro diagnostic assay for analysis of three variants in the CYP2C19 gene:  *2, *3 and *17</description>
    <arm_group_label>Prospective Genotyping - Clopidogrel</arm_group_label>
    <arm_group_label>Prospective Genotyping - Ticagrelor</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion

          -  Patient &gt;18 years of age

          -  Patient presents with ACS or stable CAD

          -  Patient is eligible for PCI

          -  Patient is willing and able to provide informed written consent

        5.3 Exclusion

          -  Patient not able to receive 12 months of dual anti-platelet therapy

          -  Failure of index PCI

          -  Patient or physician refusal to enroll in the study

          -  Patient with known CYP2C19 genotype prior to randomization

          -  Planned revascularization of any vessel within 30 days post-index procedure and/or of
             the target vessel(s) within 12 months post-procedure

          -  Anticipated discontinuation of clopidogrel or ticagrelor within the 12 month follow
             up period, example for elective surgery

          -  Serum creatinine &gt;2.5 mg/dL within 7 days of index procedure

          -  Platelet count &lt;80,000 or &gt;700,000 cells/mm3, or white blood cell count &lt;3,000
             cells/mm3 if persistent (at least 2 abnormal values) within 7 days prior to index
             procedure.

          -  History of intracranial hemorrhage

          -  Known hypersensitivity to clopidogrel or ticagrelor or any of its components

          -  Inability to take aspirin at a dosage of 100 mg or less

          -  Patient is participating in an investigational drug or device clinical trial that has
             not reached its primary endpoint

          -  Patient previously enrolled in this study

          -  Patient is pregnant, lactating, or planning to become pregnant within 12 months

          -  Patient has received an organ transplant or is on a waiting list for an organ
             transplant

          -  Patient is receiving or scheduled to receive chemotherapy within 30 days before or
             after the procedure

          -  Patient  is  receiving  immunosuppressive  therapy  or  has  known  immunosuppressive
              or autoimmune disease (e.g., human immunodeficiency virus, systemic lupus
             erythematous, etc.)

          -  Patient is receiving chronic oral anticoagulation therapy (i.e., vitamin K
             antagonist, direct thrombin inhibitor, Factor Xa inhibitor)

          -  Concomitant use of simvastatin/lovastatin &gt; 40 mg qd

          -  Concomitant  use  of  potent  CYP3A4  inhibitors  (atazanavir,  clarithromycin,
             indinavir, itraconazole, ketoconazole, nefazodone, nelfinavir, ritonavir, saquinavir,
             telithromycin and voriconazole)   or   inducers   (carbamazepine,   dexamethasone,
             phenobarbital,   phenytoin, rifampin, and rifapentine)

          -  Non-cardiac condition limiting life expectancy to less than one year, per physician
             judgment (e.g. cancer)

          -  Known history of severe hepatic impairment

          -  Patient has a history of bleeding diathesis or coagulopathy or will refuse blood
             transfusions

          -  Patient has an active pathological bleeding, such as active gastrointestinal (GI)
             bleeding

          -  Inability to take aspirin at a dosage of 100 mg or less

          -  Current substance abuse (e.g., alcohol, cocaine, heroin, etc.)
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Naveen Pereira, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Mayo Clinic</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Kelly Paulson</last_name>
    <phone>507-266-3415</phone>
    <email>paulson.kelly@mayo.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Boilson Sarah</last_name>
    <phone>507-255-2648</phone>
    <email>boilson.sarah@mayo.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Mayo Clinic in Arizona</name>
      <address>
        <city>Scottsdale</city>
        <state>Arizona</state>
        <zip>85259</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Marlene Lind, RN</last_name>
      <email>lind.marlene@mayo.edu</email>
    </contact>
    <investigator>
      <last_name>John Sweeney, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Mayo Clinic in Florida</name>
      <address>
        <city>Jacksonville</city>
        <state>Florida</state>
        <zip>32224</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Grace Staggs, RN</last_name>
      <email>staggs.estela@mayo.edu</email>
    </contact>
    <investigator>
      <last_name>Gary E Lane, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>NCH Heart Institute</name>
      <address>
        <city>Naples</city>
        <state>Florida</state>
        <zip>34102</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Suzanne Kirkland, RN</last_name>
      <phone>239-624-4242</phone>
      <email>Suzanne.Kirkland@nchmd.org</email>
    </contact>
    <investigator>
      <last_name>Adam Frank, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>NorthShore University Health System</name>
      <address>
        <city>Evanston</city>
        <state>Illinois</state>
        <zip>60201</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Elena Genova-Peeva, Ph.D.</last_name>
      <phone>847-444-5314</phone>
      <email>EGenova-Peeva@northshore.org</email>
    </contact>
    <contact_backup>
      <last_name>Jean Skelskey, RN</last_name>
      <email>JSkelskey@northshore.org</email>
    </contact_backup>
    <investigator>
      <last_name>Jorge Saucedo, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Minneapolis Heart Institute</name>
      <address>
        <city>Minneapolis</city>
        <state>Minnesota</state>
        <zip>55407</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Amy McMeans, RN</last_name>
      <phone>612-863-3895</phone>
      <email>Amy.McMeans@allina.com</email>
    </contact>
    <investigator>
      <last_name>Ivan J Chavez, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Mayo Clinic in Rochester</name>
      <address>
        <city>Rochester</city>
        <state>Minnesota</state>
        <zip>55905</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Diane Batzel</last_name>
      <email>batzel.diane@mayo.edu</email>
    </contact>
    <contact_backup>
      <last_name>Jill Boyum</last_name>
      <email>boyum.jill@mayo.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Verghese Mathew, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The Feinstein Institute for Medical Research</name>
      <address>
        <city>Manhasset</city>
        <state>New York</state>
        <zip>11030</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Mariamne Reyna</last_name>
      <phone>212-434-3362</phone>
      <email>MReyna@NSHS.edu</email>
    </contact>
    <investigator>
      <last_name>Kirk N Garratt, MSc, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>MHS, Eau Claire</name>
      <address>
        <city>Eau Claire</city>
        <state>Wisconsin</state>
        <zip>54702</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Vy T Nguyen</last_name>
      <phone>715-464-8131</phone>
      <email>Nguyen.Vy1@mayo.edu</email>
    </contact>
    <contact_backup>
      <last_name>Dawn Mrozonski, RN</last_name>
      <phone>715-838-6356</phone>
      <email>Mrozinski.Dawn@mayo.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Fearghas O'Cochlain, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Mayo Clinic Health System</name>
      <address>
        <city>LaCrosse</city>
        <state>Wisconsin</state>
        <zip>54601</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Diane Johnson, RN</last_name>
      <email>Johnson.Diane5@mayo.edu</email>
    </contact>
    <investigator>
      <last_name>Charles R Cagin, DO</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Ottawa Heart Institute</name>
      <address>
        <city>Ottawa</city>
        <state>Ontario</state>
        <zip>K1Y 4W7</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lyne Stuwe, RN</last_name>
      <email>LStuewe@ottawaheart.ca</email>
    </contact>
    <contact_backup>
      <last_name>Cheryl Charlebois, RN</last_name>
      <email>ccharlesbois@ottawaheart.ca</email>
    </contact_backup>
    <investigator>
      <last_name>Derek So, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Toronto General Hospital - UHN</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M5B 2C4</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Christina Drake, RN</last_name>
      <phone>416 340 4800</phone>
      <email>Christina.Drake@uhn.ca</email>
    </contact>
    <investigator>
      <last_name>Chris Overgaard, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Sunnybrook Health Services Center</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M4N 3M5</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sonya Jancar, RN</last_name>
      <email>Sonya.Jancar@sunnybrook.ca</email>
    </contact>
    <investigator>
      <last_name>Mina Madan, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>St Michael's Hospital</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M5B 1W8</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sandra Felix, RN</last_name>
      <email>felixS@smh.ca</email>
    </contact>
    <investigator>
      <last_name>John Graham, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Konyang University College of Medicine</name>
      <address>
        <city>Daejeon</city>
        <zip>302-718</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>YoungHee Bae</last_name>
      <phone>82-42-600-9409</phone>
      <email>prettyyh0028@naver.com</email>
    </contact>
    <investigator>
      <last_name>Jang-Ho Bae, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Chonnam National University Hospital</name>
      <address>
        <city>Gwangju</city>
        <zip>501-757</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Eun Jung Kim</last_name>
      <phone>82.62.220.5783</phone>
      <email>kej-shep@hanmail.net</email>
    </contact>
    <contact_backup>
      <last_name>Hyun Yee Gook</last_name>
      <phone>82-62-220-5783</phone>
      <email>kiznetic@hanmail.net</email>
    </contact_backup>
    <investigator>
      <last_name>Myung Ho Jeong, M.D., Ph.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Chung-Ang University Hospital</name>
      <address>
        <city>Seoul</city>
        <zip>156-755</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Sung-ho Hwang</last_name>
      <email>xxhwangxx@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Joonhwa Hong, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
    <country>Canada</country>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>April 2014</verification_date>
  <lastchanged_date>April 11, 2014</lastchanged_date>
  <firstreceived_date>December 3, 2012</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Mayo Clinic</investigator_affiliation>
    <investigator_full_name>Naveen L. Pereira</investigator_full_name>
    <investigator_title>Assistant Professor of Medicine, College of Medicine</investigator_title>
  </responsible_party>
  <keyword>percutaneous coronary intervention</keyword>
  <keyword>angioplasty</keyword>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>Yes</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Constriction, Pathologic</mesh_term>
    <mesh_term>Coronary Artery Disease</mesh_term>
    <mesh_term>Myocardial Ischemia</mesh_term>
    <mesh_term>Coronary Disease</mesh_term>
    <mesh_term>Acute Coronary Syndrome</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Clopidogrel</mesh_term>
    <mesh_term>Ticlopidine</mesh_term>
    <mesh_term>Ticagrelor</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
